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MaOBJECTIVES This randomized trial investigated to what extent loading with prasugrel can provide a more rapid peri-
interventional antiplatelet effect than clopidogrel 600 mg.
BACKGROUND Effective platelet inhibition at the start of a percutaneous coronary intervention (PCI) reduces the risk
of ischemic complications. With clopidogrel administered immediately before a PCI, effective platelet inhibition is delayed
by 2 h. Prasugrel has the potential of shortening this period.
METHODS We randomly assigned 300 P2Y12 receptor blocker–naive patients undergoing an elective PCI to loading with
clopidogrel 600 mg, prasugrel 30 mg, or prasugrel 60 mg immediately before the PCI. Platelet function was assessed
serially by impedance aggregometry. The primary endpoint was the proportion of patients with high on-treatment
platelet reactivity at 60 min after loading deﬁned as $468 aggregation units  minute (Multiplate Analyzer, Roche
Diagnostics, Mannheim, Germany).
RESULTS The 3 groups were well balanced with respect to clinical and angiographic characteristics. At 60 min, 33% of
the patients assigned to prasugrel 60 mg, 37% of patients assigned to prasugrel 30 mg, but 55% of those assigned to
clopidogrel had high on-treatment platelet reactivity (p < 0.001). At any time point starting from 30 min, prasugrel
60 mg achieved signiﬁcantly lower platelet reactivity than clopidogrel. Platelet reactivity at 60 min after prasugrel was
not signiﬁcantly different from that at 120 min after clopidogrel (p ¼ 0.18). Prasugrel 30 mg had an intermediate effect.
The 30-day incidence of bleeding events was not different among the 3 groups.
CONCLUSIONS From 30 min onward, prasugrel 60 mg achieved a stronger platelet inhibition than clopidogrel loading
in stable patients undergoing a PCI. Compared with clopidogrel, prasugrel 60 mg was associated with a twice as fast
onset of platelet inhibition. (Impact of Extent of Clopidogrel-Induced Platelet Inhibition during Elective Stent Implan-
tation on Clinical Event Rate—Advanced Loading Strategies [ExcelsiorLOAD]; DRKS00006102)
(J Am Coll Cardiol Intv 2016;9:219–27) © 2016 by the American College of Cardiology Foundation.m the aDepartment of Cardiology and Angiology II, University Heart Center Freiburg–Bad Krozingen, Bad Krozingen, Germany;
d the bCenter for Medical Biometry and Medical Informatics, University of Freiburg, Freiburg, Germany. This trial was
pported by the German Heart Foundation/German Foundation of Heart Research and the University Heart Center Freiburg–Bad
ozingen. Dr. Hochholzer has received lecture fees from Daiichi-Sankyo, Bristol-Myers Squibb, and Boehringer Ingelheim.
. Stratz has received lecture fees from Eli Lilly. Dr. Trenk has received consulting and lecture fees from AstraZeneca, Bayer, and
Lilly; consulting fees from Otsuka; and lecture fees from Bristol-Myers Squibb and Daiichi-Sankyo. All other authors have
orted that they have no relationships relevant to the contents of this paper to disclose.
nuscript received September 14, 2015; revised manuscript received September 30, 2015, accepted October 5, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
AU  min = aggregation
units 3 minute
BARC = Bleeding Academic
Research Consortium
PCI = percutaneous coronary
intervention
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220P atients undergoing an elective percu-taneous coronary intervention (PCI)need sufﬁcient platelet inhibition to
prevent ischemic complications as demon-
strated by multiple studies showing an asso-
ciation of high on-treatment platelet
reactivity with clinical outcome (1–4). Cur-
rent European and American guidelinesrecommend the use of dual antiplatelet therapy
with acetylsalicylic acid and the P2Y12 receptor
blocker clopidogrel in this setting (5,6). Although
some clinical trials have suggested no beneﬁt of pre-
treatment with clopidogrel compared with loading
in the catheterization laboratory (7,8), other trials
and a large meta-analysis showed that pre-treatment
with clopidogrel is associated with a signiﬁcantly
lower incidence of periprocedural major coronary
events in patients undergoing elective PCI (9–11).SEE PAGE 228However, even if pre-treatment of all potential PCI
candidates might be an option for the prevention of
ischemic events, this would put patients with no indi-
cation for PCI after diagnostic angiography at higher
risk of hemorrhagic complications (4,12,13). There-
fore, current guidelines discourage pre-treating elec-
tive PCI patients with clopidogrel when the coronary
anatomy is not known (6,14). There is even no recom-
mendation for pre-treatment in patients at higher
ischemic risk (15). However, these recommendations
would prevent PCI being performed immediately
after diagnostic angiography, which is logistically
desirable and avoids the risks associated with a sub-
sequent additional vascular access.
The clinical importance of sufﬁcient P2Y12 recep-
tor inhibition at the start of PCI was demonstrated
by a recent trial comparing the injectable P2Y12 re-
ceptor blocker cangrelor with loading clopidogrel
immediately before PCI (9). Cangrelor provides an
immediate onset of the antiplatelet effect, whereas
with clopidogrel, it takes at least 2 h to achieve the
effect (16–18). This initial short gap in peri-
interventional platelet inhibition was associated
with a signiﬁcant increase in myocardial infarction
and stent thrombosis. Because cangrelor is not yet
available for clinical routine use in every country,
other more potent oral loading strategies might
provide improved peri-interventional platelet inhi-
bition. Compared with loading with clopidogrel 600
mg, loading with prasugrel 60 mg is associated with
more potent platelet inhibition after only 2 h (19,20).
However, data on the very early antiplatelet effect
that reﬂect the time of coronary intervention and
therefore the highest risk of ischemic complications,in particular, in stable patients undergoing PCI, are
sparse.
Thus, this prospective, randomized trial compared
the early, peri-interventional pharmacodynamic
effect of loading with clopidogrel 600 mg, prasugrel
30 mg, or prasugrel 60 mg given immediately before
elective coronary intervention in stable patients.METHODS
STUDY DESIGN AND OBJECTIVES. The Excelsior-
LOAD (Impact of Extent of Clopidogrel-Induced
Platelet Inhibition during Elective Stent Implanta-
tion on Clinical Event Rate—Advanced Loading Stra-
tegies) trial was designed as 3-armed, controlled
PROBE (prospective, randomized, open, blinded
endpoints) phase IIIb trial with a registry cohort of
patients already pre-treated with clopidogrel
(Figure 1). Patients were enrolled in this monocentric
trial at the University Heart Center in Bad Krozingen,
Germany, from June 2014 until March 2015. The study
was approved by the ethics committee of the Uni-
versity of Freiburg (Germany) and the regulatory
agency (Federal Institute for Drugs and Medical
Devices, Bonn, Germany) and was registered at the
German Clinical Trial Register (DRKS00006102).
The objective of the ExcelsiorLOAD trial was to
compare the peri-interventional pharmacodynamic
effectiveness of loading with clopidogrel 600 mg,
prasugrel 30 mg, or prasugrel 60 mg given imme-
diately before elective PCI in stable patients. The
primary endpoint was the proportion of patients
with high on-treatment platelet reactivity tested
1 h after administration of the loading dose. Sec-
ondary endpoints included analysis of pharmaco-
dynamic effectiveness at other time points after
loading, and clinical endpoints (all fatal, ischemic,
and hemorrhagic events) within 30 days after
loading.
STUDY POPULATION. Stable patients with obstruc-
tive coronary heart disease and planned coronary
stent implantation were eligible when they were pre-
treated with aspirin and were 18 years of age or
older. Key exclusion criteria were acute myocardial
infarction; treatment with ticagrelor, prasugrel, ﬁ-
brinolytic agents, or glycoprotein IIb/IIIa inhibitors
within 7 days before enrollment; a contraindication to
aspirin or any of the study medications including
active pathological bleeding or a history of transient
ischemic attack or stroke; oral anticoagulation, or any
severe disorder of the coagulation system. Patients
already taking clopidogrel (75 mg/day for more than
4 days or loading with 600 mg more than 2 h before
FIGURE 1 Trial Flow Chart
The ﬁgure shows the ﬂow of patients in this trial. PCI ¼ percutaneous coronary intervention.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 3 , 2 0 1 6 Hochholzer et al.
F E B R U A R Y 8 , 2 0 1 6 : 2 1 9 – 2 7 The ExcelsiorLOAD Trial
221PCI) were enrolled in a registry cohort but were not
eligible for randomization.
After diagnostic angiography, patients were ran-
domized in a 1:1:1 fashion when the decision for PCI
was made. Randomization codes were computer
generated with a block size of 12 and provided in
opaque envelopes labeled with consecutive numbers.
Study medication was given immediately before the
start of the PCI.
After the PCI, all patients were treated with a daily
maintenance dose of aspirin 100 mg and clopidogrel
75 mg for at least 30 days. All other medications and
procedures were left to the discretion of the treating
physicians. All patients gave written informed con-
sent before angiography or any study procedure.LABORATORY PROCEDURES. Blood samples for
platelet function testing were taken after randomiza-
tion immediately before intake of study medication
and before beginning the PCI as well as every 30 min
thereafter for the ﬁrst 2 h and on day 1 after the PCI
immediately before taking the ﬁrst maintenance dose
ofclopidogrel75mg.Bloodwascollected in2.7-ml tubes
containing recombinant hirudin (45 mg/ml) (Sarstedt
AG & Co., Nümbrecht, Germany). Adenosine diphos-
phate (6.4 mM)–induced platelet aggregation was
assessed in whole blood by impedance aggregometry
according to manufacturer’s instructions (adenosine
diphosphate test without prostaglandin E1, Multiplate
Analyzer, Roche Diagnostics, Mannheim, Germany).
The area under the curve of aggregation units was
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222recorded over 6 min and results were described as
aggregation units  minute (AU  min). High
on-treatment platelet reactivity was deﬁned as $468
AU  min according to previously published data
and recommendations of a consensus document (2,3).
ADJUDICATION AND DEFINITION OF CLINICAL
ENDPOINTS. All patients were followed for 30 days.
In addition to results obtained from clinical follow-
up, an automated computer algorithm reported any
additional diagnostic procedure or even minor
change in biomarkers, as well as any additional
appointments (e.g., to the outpatient department
during follow-up). All reported potential clinical
events were adjudicated by 2 independent cardiolo-
gists blinded to the randomized treatment.
Myocardial infarction was classiﬁed according to
the Third Universal Deﬁnition ofMyocardial Infarction
(21). High-sensitivity cardiac troponin was tested in all
patients at 8, 16, and 24 h after PCI. In addition to a
signiﬁcant increase and decrease in troponin, new
typical cardiac symptoms, electrocardiographic
changes, or imaging results were needed for diagnosis.
Bleeding was classiﬁed according to the consensus
report from the Bleeding Academic Research Con-
sortium (BARC) and the Thrombolysis In Myocardial
Infarction criteria (22). To detect even minimal
bleeding events, the vascular access site of all pa-
tients was examined by dedicated nurses immedi-
ately after PCI as well as the next day.
STATISTICS AND POWER CALCULATION. The pri-
mary analysis was the comparison of the proportion
of patients with high on-treatment platelet reactivity
of clopidogrel 600 mg and prasugrel 60 mg 1 h after
administration of the loading dose (test for superior-
ity, Fisher exact test at a level of signiﬁcance of 2.5%).
If the result of this test was positive, hierarchical
testing comparing clopidogrel 600 mg and prasugrel
30 mg followed by prasugrel 60 mg and prasugrel 30
mg by was done. Assuming an incidence of high on-
treatment platelet reactivity as assessed by the Mul-
tiplate Analyzer of 17% for clopidogrel 600 mg and 3%
for prasugrel 60 mg based on data of clinical cohorts
(23,24), a sample size of 100 for each group was
calculated to achieve a power of 90% at a level of
signiﬁcance of 2.5%. The modiﬁed intention-to-treat-
population including all randomized patients being
treated at least with the study loading dose was used
for these analyses.
In general, discrete variables are reported as count
(percentage) and continuous variables as median
(interquartile range). For discrete variables, differ-
ences between groups were tested by the Fisher exact
test. For continuous variables, the Mann-WhitneyU or Kruskal-Wallis test was used. In 2-sided tests, a
p value <0.05 was regarded as signiﬁcant. Statistical
analyses were run with IBM SPSS, version 22.0 (IBM
Corporation, Armonk, New York).RESULTS
STUDY POPULATION. Baseline characteristics of ran-
domized patients were well balanced between cohorts
(Table 1). Patients were predominantly male, the mean
age was 68 years, 26% were diabetic, and more than
50% has a diagnosis of 3-vessel disease. Proton pump
inhibitors were used in 28%, a radial access for inter-
vention in 55%, and vascular closure systems in 3%.
Patients in the registry cohort did signiﬁcantly
differ from randomized patients with respect to car-
diac history, coronary ﬁndings, and procedural char-
acteristics (Online Table 1).
PHARMACODYNAMIC RESULTS. The primary endpoint
deﬁned as the proportion of patients with high
on-treatment platelet reactivity tested 1 h after
administration of the loading dose was seen in 55% of
patients loaded with clopidogrel 600 mg, in 37% of
patients receiving prasugrel 30mg, and 33%of patients
receiving prasugrel 60 mg. All 3 pre-deﬁned compari-
sons showed signiﬁcant results (clopidogrel 600mg vs.
prasugrel 60 mg; p < 0.001; clopidogrel 600 mg vs.
prasugrel 30 mg; p ¼ 0.008; prasugrel 30 mg vs. pra-
sugrel 60mg; p¼0.024). Already at 30min as well as at
any time point up to 2 h after loading, prasugrel 60 mg
was associated with a signiﬁcantly lower proportion of
patients with high on-treatment platelet reactivity
(Figure 2). Prasugrel 30mgwas associatedwith a higher
response compared with clopidogrel 600mg only at 30
and 60 min after loading.
Analyzing platelet reactivity as a continuous vari-
able showed similar ﬁndings (Figure 3). Prasugrel
60 mg was associated with lower platelet reactivity
compared with clopidogrel 600 mg at any time point
after loading. Platelet reactivity with prasugrel 60 mg
after 30 min was not signiﬁcantly different from
platelet reactivity with clopidogrel 600 mg after
60 min (p ¼ 0.76). Similar ﬁndings were obtained for
the comparison of prasugrel 60 mg after 60 min and
clopidogrel 600 mg after 120 min (p ¼ 0.18). Treat-
ment with prasugrel 30 mg did achieve this only
starting at 60 min after loading. When comparing
prasugrel 30 mg and 60 mg, the 60-mg loading dose
was associated with lower platelet reactivity in the
early peri-interventional period from 30 to 90 min.
On day 1, the number of patients with high on-
treatment platelet reactivity was low and similar in
all 3 cohorts (Online Figure 1). Platelet aggregation
TABLE 1 Baseline Characteristics*
Clopidogrel 600 mg
(n ¼ 100)
Prasugrel 30 mg
(n ¼ 100)
Prasugrel 60 mg
(n ¼ 100)
Age, yrs 68 (60–74) 70 (64–76) 68 (59–75)
Male 78 79 85
Active smoker 6 6 6
Arterial hypertension 83 76 81
Hypercholesterolemia 84 76 82
Diabetes mellitus 27 25 26
Body mass index, kg/m2 27.7 (25.6–30.2) 27.4 (25.3–30.4) 27.7 (25.2–30.1)
Hemoglobin, g/dl 14.4 (13.6–15.3) 14.5 (13.7–15.3) 14.4 (13.6–15.4)
Platelet count, 109/l 215 (186–246) 219 (185–255) 211 (167–244)
Glomerular ﬁltration rate, ml/min 79 (64–91) 78 (63–90) 78 (63–89)
High-sensitivity troponin T, ng/l 9 (7–14) 11 (7–17) 10 (8–13)
Medications
b-blocker 73 68 72
ACE inhibitor 50 60 47
Calcium channel blocker 26 24 25
Statin 95 95 98
Proton pump inhibitor 22 28 34
Previous balloon angioplasty 33 43 51
Previous CABG 14 7 18
Previous myocardial infarction 14 18 19
Reduced LV ejection fraction† 17 28 21
Coronary angiography result
1-vessel disease 20 21 14
2-vessel disease 32 28 26
3-vessel disease 48 51 60
Treated vessel
Left anterior descending 46 42 51
Left circumﬂex 41 35 49
Right coronary artery 39 42 30
Bypass 1 1 3
Radial access 54 55 55
Vascular closure system used 4 3 2
Sheath size >6-F 5 2 3
Values are median (interquartile range) or n. *There were no signiﬁcant differences in the 3 groups (p > 0.15 for
all comparisons). †Left ventricular ejection fraction <55%.
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypass grafting; LV ¼ left ventricular.
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223analyzed as a continuous variable on day 1 was
similar in both prasugrel cohorts (p ¼ 0.15) but lower
than in patients receiving clopidogrel 600 mg
(p < 0.001) even if the numerical differences were
small (Online Figure 2).
The registry cohort of patients pre-treated with
clopidogrel showed similar rates of patients with high
on-treatment platelet reactivity as compared with the
cohort of patients randomized to clopidogrel 600 mg
at 2 h and 1 day after loading. When analyzing platelet
reactivity as a continuous variable, the mean platelet
reactivity was lower in patients in the registry cohort
compared with patients who received clopidogrel 600
mg immediately before PCI (p ¼ 0.02).
There were no sex-based differences in antiplatelet
response in the 3 study regimens.
CLINICAL SAFETY PARAMETERS. Complete clinical
follow-up was available for 299 of 300 randomized
patients. Fatal events occurred in 1 patient random-
ized to prasugrel 60 mg and 1 patient from the reg-
istry cohort. Both events were adjudicated as most
likely not related to study procedures (Table 2, Online
Table 2). The incidence of ischemic and bleeding
events was comparable between randomized cohorts.
BARC 2 to 5 bleeding events occurred in 7% of ran-
domized patients and were mainly mild and located
at the vascular access site. Major bleeding events
(BARC 3 to 5) were recorded in 3 of the 300 random-
ized patients, and Thrombolysis In Myocardial
Infarction major bleeding in only 1 patient random-
ized to prasugrel 30 mg (vascular access site bleeding
with a decrease in hemoglobin of 5.1 g/dl). In the
registry cohort, minor and major bleeding events
were reported in 18% of patients.
DISCUSSION
This prospective, randomized trial compared the peri-
interventional pharmacodynamics of loading with
clopidogrel 600 mg, prasugrel 30 mg, or prasugrel
60 mg given immediately before elective PCI in stable
patients. Key ﬁndings are that loading with prasugrel
60 mg achieves a sufﬁcient antiplatelet effect as soon
as 30 min after loading in approximately one-half of
patients and in more than two-thirds of patients after
60 min. This strategy is signiﬁcantly more effective
than loading with clopidogrel 600mg at all tested time
points and reaches within 1 h a similar effect as the full
effect of loading with clopidogrel. Overall, prasugrel
60 mg is associated with a twice as fast onset of
platelet inhibition compared with clopidogrel. Treat-
ment with prasugrel 30mg is, in part, also signiﬁcantly
more effective than clopidogrel 600 mg but less effec-
tive than prasugrel 60 mg. On day 1 after loading, thenumber of patients with high on-treatment platelet
reactivity is similar with all 3 loading strategies, and
differences in absolute platelet reactivity are numeri-
cally small. All 3 loading strategies appear to be safe
with respect to clinical outcomes and in particular to
bleeding.
Suboptimal platelet inhibition is clearly associated
with a worse clinical outcome in patients undergoing
elective PCI (1–3,25). Pre-treatment with clopidogrel
has been shown to reduce periprocedural major cor-
onary events (4,9–11). However, given the conﬂicting
data, current guidelines do not support this approach
in stable patients and or in patients with non–ST-
segment elevation acute coronary syndrome (6,14,15).
It is listed only as an option for patients with a high
probability of signiﬁcant coronary heart disease.
Thus, loading with prasugrel immediately before PCI
FIGURE 3 ADP-Ind
*p< 0.001 compared
30min: p¼ 0.001; at
Whiskers indicate 95%
reactivity ($468 AU
FIGURE 2 Proportion of Patients With High On-Treatment Platelet Reactivity
High on-treatment platelet reactivity $468 AU  min area under the curve of aggregation
 min. *p < 0.001. †p < 0.025 compared with clopidogrel 600 mg. AU ¼ aggregation
unit(s); n.s. ¼ not signiﬁcant.
TABLE 2 Clinical Safety Parameters*
Clopidogrel
600 mg
(n ¼ 100)
Prasugrel
30 mg
(n ¼ 100)
Prasugrel
60 mg
(n ¼ 100)
Death† 0 0 1
Myocardial infarction‡ 4 4 3
Target vessel
revascularization
1 0 1
Ischemic stroke 1 1 0
TIMI bleeding
Minimal 5 10 4
Minor 0 0 1
Major 0 1 0
BARC 2–5 bleeding 5 11 5
BARC 2 5 9 4
BARC 3 0 2 1
Location of bleeding
Vascular access site 5 8 3
Epistaxis 0 0 1
Hematuria 0 2 0
Gastrointestinal 0 1 0
Pericardial 0 0 1
Values are n. *There were no signiﬁcant differences between the 3 groups
(p > 0.15 for all comparisons). †Pneumonia with acute respiratory distress syn-
drome at day 12 following randomization. ‡Coded according to Universal Deﬁnition
of Myocardial Infarction (all events were type 4a myocardial infarctions).
BARC ¼ Bleeding Academic Research Consortium; TIMI ¼ Thrombolysis In
Myocardial Infarction.
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224might be an interesting alternative. Compared with
loading with clopidogrel 600 mg, prasugrel 60 mg is
associated with a more robust antiplatelet effect
(19,26). Current guidelines list loading with prasugrel
as an option by expert opinion for speciﬁc high-risk
situations of elective stenting (14). However, datauced Platelet Reactivity as a Linear Variable
with clopidogrel 600mg. Comparison of prasugrel 30mg with 60mg at
60min: p¼ 0.001; at 90min: p¼ 0.02; all other comparisons: p> 0.10.
percentile. Dashed line indicates cutoff for high on-treatment platelet
min). ADP¼ adenosine diphosphate; AU¼ aggregation unit(s).on the very early antiplatelet effect, which reﬂects
the time of coronary intervention and therefore of
highest risk of ischemic complications, and in stable
patients in particular, were sparse. Most studies up to
the present trial mainly enrolled either healthy vol-
unteers or patients with acute coronary syndromes,
evaluated platelet function only at later time points,
and did not use commonly accepted cutoffs for high
on-treatment platelet reactivity (19,20,27).
The present trial demonstrated that loading with
prasugrel 60 mg achieved as soon as 1 h a mean an-
tiplatelet effect similar to the maximal effect seen
several hours after loading with clopidogrel 600 mg.
It is unknown so far whether this remaining short
initial gap in platelet inhibition seen with prasugrel is
of clinical relevance. The ﬁndings of the ACCOAST
(Comparison of Prasugrel at the Time of Percutaneous
Coronary Intervention or as Pretreatment at the Time
of Diagnosis in Patients With Non-ST Elevation
Myocardial Infarction) trial do not suggest a major
role of a 1-h delay in effective platelet inhibition (28).
The ACCOAST trial compared prasugrel pre-treatment
with prasugrel given immediately before PCI in pa-
tients with non–ST-segment elevation myocardial
infarction. A platelet function substudy revealed that
at 1 to 2 h after the start of PCI, patients in the no
pre-treatment group achieved the same level of
platelet inhibition as patients in the pre-treatment
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225group before PCI. In the main study, this w1-h lapse
in platelet inhibition was not associated with any
detectable increase in ischemic events. These data
indicate that the onset of antiplatelet effects with
prasugrel immediately before PCI appears to be suf-
ﬁciently prompt. It should be kept in mind, however,
that the ACCOAST trial was performed in the setting
of acute coronary syndromes. It is unknown whether
inferences from the ACCOAST trial can be applied to
patients with stable coronary disease.
The clinical safety of loading with prasugrel fol-
lowed by maintenance therapy with clopidogrel was
also recently tested in a small retrospective study
enrolling 102 patients (29). Only very few ischemic
and no major bleeding events were reported in this
cohort of stable and unstable patients undergoing
PCI. A subsequent larger retrospective study with 326
consecutive patients compared this approach with
loading with clopidogrel. There were no signiﬁcant
differences in clinical outcome including bleeding
(30), similar to that seen in the present trial. Because
platelet reactivity on day 1 after loading did not show
major differences between the 3 loading strategies, it
appears unlikely that initial loading with prasugrel
followed by clopidogrel maintenance therapy would
be associated with a higher incidence of bleeding
after the early peri-interventional period.
A key feature of this trial was the inclusion of the
lower loading dose of prasugrel 30 mg. Such a lower
loading dose can achieve a stronger antiplatelet effect
compared with clopidogrel and might be beneﬁcial
with respect to bleeding risk compared with loading
with prasugrel 60 mg, as demonstrated in previous
studies (20,31). In the present trial, loading with
prasugrel 30 mg achieved, at least in part, a signiﬁ-
cantly faster and stronger early antiplatelet effect
compared with clopidogrel 600 mg. The trend toward
a higher incidence of hemorrhagic events compared
with loading with clopidogrel 600 mg or prasugrel
60 mg is most likely a matter of chance, with the vast
majority of events fulﬁlling only the Thrombolysis In
Myocardial Infarction minimal bleeding criteria.
An alternative treatment option would have been
the injectable P2Y12 receptor blocker cangrelor, which
can provide an immediate onset of an antiplatelet
effect (9,17) and even potentiate the effects of pra-
sugrel (32). However, there are studies indicating a
pharmacodynamic interaction of cangrelor with clo-
pidogrel or prasugrel preventing the P2Y12 receptor
binding of the active metabolite of thienopyridines
(25,33–35) but not of the reversible binding drug
ticagrelor (36). Thus, the optimal transitioning strat-
egy from cangrelor to oral adenosine diphosphate
receptor inhibitors still needs to be deﬁned.Another option for peri-interventional platelet
inhibitionwould have been loadingwith the reversible
binding P2Y12 receptor blocker ticagrelor. This drug
archives its maximal effect of platelet inhibition
within the ﬁrst 2 h after loading (37). However, similar
to cangrelor, there are safety concerns regarding
switching from ticagrelor to thienopyridines accord-
ing to the results of the SWAP-2 (Switching Anti
Platelet-2) trial, and the optimal transitioning strategy
is still unknown (38).
Compared with reversible P2Y12 receptor blockers,
there is no known pharmacodynamic interaction of
prasugrel with clopidogrel, given the irreversible
mode of action of both compounds (39). Taken
together, loading with prasugrel followed by mainte-
nance therapy with clopidogrel may become a valu-
able and safe option in stable patients undergoing PCI
and in particular for high-risk coronary interventions
critically depending on sufﬁcient peri-interventional
platelet inhibition. Whether this strategy can achieve
a similar reduction in early ischemic events compared
with cangrelor needs to be proved in upcoming trials
powered for clinical outcomes.
STUDY LIMITATIONS. This trial was only powered for
pharmacodynamic endpoints. Even if there were no
signiﬁcant differences between groups regarding
clinical endpoints, the efﬁciency and safety of the
tested approach can only be validated by a larger
randomized trial.
CONCLUSIONS
In stable patients undergoing PCI, loading with pra-
sugrel 60 mg is signiﬁcantly more effective after 30
min than loading with clopidogrel 600 mg. This
strategy achieves within 1 h an effect similar to the
full effect of loading with clopidogrel. Overall, pra-
sugrel 60 mg is associated with a twice as fast onset of
platelet inhibition compared with clopidogrel. This
study does not raise any safety concerns with regard
to prasugrel loading for PCI in patients with stable
angina. Although deﬁnite proof of the safety and
efﬁcacy of this regimen in stable disease is lacking,
it might be considered an option for ad hoc PCI,
particularly in high-risk settings.
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WHAT IS NEXT? Because deﬁnite proof of the safety
and efﬁcacy of loading with prasugrel 60 mg followed by
clopidogrel maintenance therapy in stable disease is
lacking, further evaluation of this strategy in a prospec-
tive outcome trial is needed.
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